Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daratumumab - Janssen Biotech

Drug Profile

Daratumumab - Janssen Biotech

Alternative Names: Anti-CD38-monoclonal-antibody-Genmab; DALINVI; Dara-IV; Darasarex; daratumumab and hyaluronidase-fihj; DARZALEX; DARZALEX SC; Humanised anti-CD38 monoclonal antibody; HuMax-CD38; HuMax®-CD38 - Genmab; JNJ-54767414

Latest Information Update: 13 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Developer Amgen; Boston Medical Center; Bristol-Myers Squibb; Dana-Farber Cancer Institute; French Innovative Leukemia Organisation; Genentech; Genmab; Janssen Biotech; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Innovative Medicine; M. D. Anderson Cancer Center; Onyx Pharmaceuticals; Syros Pharmaceuticals; Weill Cornell Medical College
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Phagocyte stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Amyloid light-chain amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Registered Amyloid light-chain amyloidosis
  • Phase III Plasmablastic lymphoma
  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Myelodysplastic syndromes; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Solid tumours
  • Phase I Prostate cancer
  • Suspended Non-small cell lung cancer

Most Recent Events

  • 06 Mar 2024 Preregistration for Multiple myeloma (Combination therapy, Newly diagnosed) in European Union (SC)
  • 06 Mar 2024 Efficacy and adverse events data from phase III Perseus trial in Multiple myeloma released by Johnson & Johnson
  • 31 Jan 2024 Daratumumab is still in phase I trials for Prostate cancer in USA (NCT03177460)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top